Takeda Pharmaceutical Co. $TAK Shares Purchased by Boston Partners

Key Points

• Boston Partners increased its stake in Takeda Pharmaceutical by 91.2%, now owning 132,107 shares valued at approximately $1.96 million as of the latest SEC filing.
• Other institutional investors also made significant adjustments, with FNY Investment Advisers LLC and Fifth Third Bancorp establishing new stakes and boosting positions, indicating a growing interest in Takeda.
• Takeda reported a quarterly EPS of $0.52, exceeding analyst expectations, but revenue fell short of estimates at $7.45 billion versus $7.96 billion expected.

Boston Partners grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 91.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 132,107 shares of the company's stock after buying an additional 63,024 shares during the period. Boston Partners' holdings in Takeda Pharmaceutical were worth $1,964,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in TAK. FNY Investment Advisers LLC acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth about $37,000. Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after buying an additional 1,045 shares during the last quarter. Fifth Third Bancorp increased its holdings in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after buying an additional 2,411 shares during the period. Point72 Hong Kong Ltd purchased a new position in Takeda Pharmaceutical during the 4th quarter worth approximately $94,000. Finally, GAMMA Investing LLC lifted its stake in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after acquiring an additional 1,296 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded down $0.1850 on Thursday, hitting $15.2950. The company had a trading volume of 2,686,707 shares, compared to its average volume of 2,550,534. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.56. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market cap of $48.67 billion, a P/E ratio of 50.98 and a beta of 0.22. The company has a 50-day moving average price of $14.80 and a 200-day moving average price of $14.65.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, equities research analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.